Literature DB >> 10883917

Regression of a presumed meningioma with the antiestrogen agent mepitiostane. Case report.

S Oura1, T Sakurai, G Yoshimura, T Tamaki, T Umemura, Y Kokawa, O Masuo, Y Naito.   

Abstract

This 68-year-old woman underwent a distal gastrectomy for gastric cancer in August 1994. A presumed meningioma of the falx was found incidentally on a staging examination of the gastric cancer, but the meningioma was not treated with surgery. Instead, after gastrectomy the patient received tegafur as adjuvant chemotherapy until February 1996, when she was readmitted to the hospital because of loss of appetite and emaciation but with no recurrence of the gastric cancer. A computerized tomography scan obtained during this second admission showed no change in the meningioma. To improve her general condition, tegafur was discontinued and she was started on a course of the antiestrogen agent mepitiostane. Administration of mepitiostane for approximately 2 years resulted in a marked regression (73%) of the meningioma. This is the first reported case of a presumed meningioma that regressed as a result of use of the antiestrogen agent mepitiostane.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10883917     DOI: 10.3171/jns.2000.93.1.0132

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  3 in total

1.  Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression.

Authors:  Katariina Korhonen; Tiina Salminen; Jani Raitanen; Anssi Auvinen; Jorma Isola; Hannu Haapasalo
Journal:  J Neurooncol       Date:  2006-05-13       Impact factor: 4.130

Review 2.  Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas.

Authors:  Chrissa Sioka; Athanassios P Kyritsis
Journal:  J Neurooncol       Date:  2008-11-21       Impact factor: 4.130

3.  Spontaneous regression of a posterior fossa meningioma: A case report.

Authors:  Maya Takada; Kiyoyuki Yanaka; Kazuhiro Nakamura; Ken Akimoto; Hayato Takeda; Eiichi Ishikawa
Journal:  Surg Neurol Int       Date:  2022-08-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.